Last updated on January 2019

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Brief description of study

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Clinical Study Identifier: NCT03072238

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: CO39303 ...

Meir Medical Center; Oncology
Kfar-Saba, Israel
  Connect »

Reference Study ID Number: CO39303 ...

Chaim Sheba medical center, Oncology division
Ramat Gan, Israel
  Connect »

Reference Study ID Number: CO39303 ...

Soroka Medical Center; Oncology Dept
Beer Sheva, Israel
  Connect »

Reference Study ID Number: CO39303 ...

Belinson Medical Center, Division of Oncology
Petach Tikva, Israel
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.